HLS Therapeutics (TSE:HLS) Stock Rating Reaffirmed by Raymond James


Share on StockTwits

HLS Therapeutics (TSE:HLS)‘s stock had its “outperform” rating reiterated by Raymond James in a report issued on Tuesday, Stock Target Advisor reports. They currently have a C$28.00 target price on the stock. Raymond James’ price target suggests a potential upside of 49.02% from the company’s current price.

Separately, Canaccord Genuity upped their price target on HLS Therapeutics to C$33.00 and gave the stock a “strong-buy” rating in a research note on Friday, March 19th.

Shares of HLS Therapeutics stock traded down C$0.21 on Tuesday, hitting C$18.79. 32,300 shares of the company’s stock traded hands, compared to its average volume of 35,346. HLS Therapeutics has a one year low of C$13.35 and a one year high of C$21.76. The company has a debt-to-equity ratio of 66.02, a current ratio of 1.29 and a quick ratio of 0.93. The company has a fifty day moving average of C$19.74 and a two-hundred day moving average of C$17.72. The company has a market capitalization of C$597.94 million and a price-to-earnings ratio of -31.58.

HLS Therapeutics (TSE:HLS) last announced its earnings results on Thursday, March 18th. The company reported C($0.30) EPS for the quarter, missing the consensus estimate of C($0.12) by C($0.18). The company had revenue of C$21.49 million during the quarter, compared to the consensus estimate of C$20.52 million. Equities research analysts anticipate that HLS Therapeutics will post 0.4199999 earnings per share for the current year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. Its lead product is Clozaril, an atypical antipsychotic used in the treatment of schizophrenia.

Featured Article: Sell-Side Analysts

Stock Target Advisor

Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.